LabCorp (LH)

Executive Summary

LabCorp (NYSE: LH) is a global life sciences leader providing comprehensive diagnostic laboratory services and drug development solutions through its Covance division. With a mission to improve health and improve lives, the company integrates diagnostic insights with clinical research to accelerate healthcare innovation. In 2025, LabCorp reported steady revenue growth driven by strong demand for its core testing services and a modest recovery in its drug development segment. The company continues to invest in advanced diagnostics, including liquid biopsy and precision medicine, while expanding its reach in central lab services for biopharma. Despite headwinds from healthcare utilization normalization and pricing pressures, LabCorp's diversified business model and scale provide resilience. Looking ahead, the company is well-positioned to benefit from aging demographics, increasing chronic disease prevalence, and the ongoing shift toward value-based care. Key near-term catalysts include execution on cost savings initiatives and potential share repurchases, though the drug development pipeline remains a longer-term growth driver.

Upcoming Catalysts (preview)

• Q3 2026Q2 2026 Earnings Release90% success
• TBDPotential FDA Approval for EMB-01 in Neoplasms15% success
• Q4 2026Major Contract Win in Drug Development Division30% success